Epidemiology of Lyme Disease, Nova Scotia, Canada, 2002–2013
| Autor: | Sarah Fleming, Teri J. Cole, David Haldane, Richard Gould, Michael A. Drebot, Emily Schleihauf, Maureen Baikie, Todd F. Hatchette, Robbin Lindsay, B. Lynn Johnston, Angela Mask |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Epidemiology vector-borne infections lcsh:Medicine Disease Vectors Lyme disease Seroepidemiologic Studies Child Aged 80 and over education.field_of_study seroprevalence biology Incidence (epidemiology) Middle Aged Nova Scotia Infectious Diseases Ixodes scapularis Child Preschool Female geographic locations Adult Microbiology (medical) Canada medicine.medical_specialty Adolescent Population Epidemiology of Lyme Disease Nova Scotia Canada 2002–2013 lcsh:Infectious and parasitic diseases ticks health services administration Internal medicine medicine Animals Humans Seroprevalence lcsh:RC109-216 Borrelia burgdorferi education Aged Ixodes business.industry Research lcsh:R Infant biology.organism_classification medicine.disease Virology business |
| Zdroj: | Emerging Infectious Diseases Emerging Infectious Diseases, Vol 21, Iss 10, Pp 1751-1758 (2015) |
| ISSN: | 1080-6059 1080-6040 |
| DOI: | 10.3201/eid2110.141640 |
| Popis: | Nova Scotia has the highest reported incidence in Canada, but risk is localized to identified disease-endemic regions. Ixodes scapularis ticks, which transmit Borrelia burgdorferi, the causative agent of Lyme disease (LD), are endemic to at least 6 regions of Nova Scotia, Canada. To assess the epidemiology and prevalence of LD in Nova Scotia, we analyzed data from 329 persons with LD reported in Nova Scotia during 2002–2013. Most patients reported symptoms of early localized infection with rash (89.7%), influenza-like illness (69.6%), or both; clinician-diagnosed erythema migrans was documented for 53.2%. In a separate serosurvey, of 1,855 serum samples screened for antibodies to B. burgdorferi, 2 were borderline positive (both with an indeterminate IgG on Western blot), resulting in an estimated seroprevalence of 0.14% (95% CI 0.02%–0.51%). Although LD incidence in Nova Scotia has risen sharply since 2002 and is the highest in Canada (16/100,000 population in 2013), the estimated number of residents with evidence of infection is low, and risk is localized to currently identified LD-endemic regions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |